BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 24862260)

  • 1. Regulation of cancer metabolism by oncogenes and tumor suppressors.
    Iurlaro R; León-Annicchiarico CL; Muñoz-Pinedo C
    Methods Enzymol; 2014; 542():59-80. PubMed ID: 24862260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.
    Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A
    Hum Mutat; 2013 Feb; 34(2):330-7. PubMed ID: 23292961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia.
    Sun HL; Liu YN; Huang YT; Pan SL; Huang DY; Guh JH; Lee FY; Kuo SC; Teng CM
    Oncogene; 2007 Jun; 26(27):3941-51. PubMed ID: 17213816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN, more than the AKT pathway.
    Blanco-Aparicio C; Renner O; Leal JF; Carnero A
    Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Desmethylanhydroicaritin inhibits NF-kappaB-regulated inflammatory gene expression by modulating the redox-sensitive PI3K/PTEN/Akt pathway.
    Kim JH; Lee G; Cho YL; Kim CK; Han S; Lee H; Choi JS; Choe J; Won MH; Kwon YG; Ha KS; Kim YM
    Eur J Pharmacol; 2009 Jan; 602(2-3):422-31. PubMed ID: 19027002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2.
    Nowak DG; Cho H; Herzka T; Watrud K; DeMarco DV; Wang VM; Senturk S; Fellmann C; Ding D; Beinortas T; Kleinman D; Chen M; Sordella R; Wilkinson JE; Castillo-Martin M; Cordon-Cardo C; Robinson BD; Trotman LC
    Cancer Discov; 2015 Jun; 5(6):636-51. PubMed ID: 25829425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?
    Menendez JA; Colomer R; Lupu R
    Med Hypotheses; 2005; 64(2):342-9. PubMed ID: 15607569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
    Guo C; Gasparian AV; Zhuang Z; Bosykh DA; Komar AA; Gudkov AV; Gurova KV
    Oncogene; 2009 Feb; 28(8):1151-61. PubMed ID: 19137016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signaling to the ribosome in cancer--It is more than just mTORC1.
    Hannan KM; Sanij E; Hein N; Hannan RD; Pearson RB
    IUBMB Life; 2011 Feb; 63(2):79-85. PubMed ID: 21360636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes.
    Amundadottir LT; Leder P
    Oncogene; 1998 Feb; 16(6):737-46. PubMed ID: 9488037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence.
    Barnoud T; Schmidt ML; Donninger H; Clark GJ
    Cancer Lett; 2017 Aug; 400():30-36. PubMed ID: 28455242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells.
    Gao N; Nester RA; Sarkar MA
    Toxicol Appl Pharmacol; 2004 Apr; 196(1):124-35. PubMed ID: 15050414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bidirectional regulation of nuclear factor-κB and mammalian target of rapamycin signaling functionally links Bnip3 gene repression and cell survival of ventricular myocytes.
    Dhingra R; Gang H; Wang Y; Biala AK; Aviv Y; Margulets V; Tee A; Kirshenbaum LA
    Circ Heart Fail; 2013 Mar; 6(2):335-43. PubMed ID: 23395931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonistic functional duality of cancer genes.
    Stepanenko AA; Vassetzky YS; Kavsan VM
    Gene; 2013 Oct; 529(2):199-207. PubMed ID: 23933273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling interplay between transforming growth factor-β receptor and PI3K/AKT pathways in cancer.
    Zhang L; Zhou F; ten Dijke P
    Trends Biochem Sci; 2013 Dec; 38(12):612-20. PubMed ID: 24239264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Oncogenes and tumor suppressor genes in the signal transduction pathways of growth factors].
    Buday L
    Orv Hetil; 1994 Nov; 135(47):2579-84. PubMed ID: 7824256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenes strike a balance between cellular growth and homeostasis.
    Qiu B; Simon MC
    Semin Cell Dev Biol; 2015 Jul; 43():3-10. PubMed ID: 26277544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
    Lv J; Wang J; Chang S; Liu M; Pang X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferation and tissue remodeling in cancer: the hallmarks revisited.
    Markert EK; Levine AJ; Vazquez A
    Cell Death Dis; 2012 Oct; 3(10):e397. PubMed ID: 23034332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic regulation of tumor metabolic reprogramming.
    Tarrado-Castellarnau M; de Atauri P; Cascante M
    Oncotarget; 2016 Sep; 7(38):62726-62753. PubMed ID: 28040803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.